Co-administration With the Pharmacological Chaperone AT1001 Increases Recombinant Human α-Galactosidase A Tissue Uptake and Improves Substrate Reduction in Fabry Mice
Molecular Therapy2012Vol. 20(4), pp. 717–726
Citations Over TimeTop 10% of 2012 papers
Elfrida R. Benjamin, Richie Khanna, Adriane Schilling, John J. Flanagan, Lee Pellegrino, Nastry Brignol, Yi Lun, Darlene Guillen, Brian Ranes, Michelle Frascella, Rebecca Soska, Jessie Feng, Leo B. Dungan, Brandy Young, David J. Lockhart, Kenneth J. Valenzano
Related Papers
- → AAV2/6 Gene Therapy in a Murine Model of Fabry Disease Results in Supraphysiological Enzyme Activity and Effective Substrate Reduction(2020)53 cited
- → Use of a Modified α-N-Acetylgalactosaminidase in the Development of Enzyme Replacement Therapy for Fabry Disease(2009)53 cited
- → Glucosylceramide synthase inhibition with lucerastat lowers globotriaosylceramide and lysosome staining in cultured fibroblasts from Fabry patients with different mutation types(2018)42 cited
- → Fabry disease: where are we now?(2020)33 cited
- → Human α-Galactosidase A Mutants: Priceless Tools to Develop Novel Therapies for Fabry Disease(2021)20 cited